Aligos Therapeutics IncALGS
Price$5.63

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value not published yet, our data-reliability standards weren't met; method estimates belowbased on filings through 30 Jun 2026
Market Price $5.63Price as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: -1.2%/yr (balance of the path).0.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 6-0.4%Yr 70.5%Yr 81.3%Yr 92.2%Yr 103.0%
-1.2% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 13.3%
Volatility vs market (adjusted beta)1.87

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetAligos Therapeutics IncALGSHealth Care
Valuation
P/E—
P/S8.8×
P/B1.8×
EV / Revenue0.6×
EV / EBITDA—
Profitability
Gross margin100.0%
Operating margin-4,024.9%
Net margin-2,031.1%
FCF margin-2,521.3%
Returns
ROE-238.2%
ROA-114.5%
ROIC—
Growth
Revenue growth (YoY)3.6%
5-yr fwd EPS growth0.0%
Financial strength
Debt / Equity0.00×
Current ratio2.19×
Altman Z-Score-16.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.